.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The U.S. Food and Drug Administration (FDA) recently issued a stern warning to Medline Industries regarding Medline syringe defects found in their NAMIC division. These specific syringes are frequently used in cardiovascular procedures to inject contrast dye into patients' blood vessels. Consequently, the regulator cautioned the company about potential penal actions if it fails to resolve these safety issues promptly. Clinicians should be aware that the defects involve syringes disconnecting from manifolds during use.
The FDA highlighted that Medline failed to take appropriate action following numerous complaints about the devices. Specifically, the company received over 220 complaints regarding technical failures. One reported incident involved a life-threatening air embolism, which occurs when air enters the bloodstream. Furthermore, another case resulted in a clinician being exposed to a biohazard. Although Medline's internal analysis identified air embolism as a severe risk, the company inconsistently rated the overall risk as low. Therefore, the regulator expressed serious concerns about the company's risk assessment processes.
Following an inspection in December 2025, the FDA cited the facility for poor cleaning practices and inadequate safety testing. Because attempted fixes failed to stop the problem, complaint rates rose throughout 2025. Eventually, Medline initiated a product recall and filed a removal report in March 2026. However, the agency warned that failure to correct these violations could lead to product seizures or court action. Medical professionals should check their procedure kits for affected NAMIC syringes to ensure patient safety.
Q1: What is the primary cause of the Medline syringe defects?
The company linked the syringe disconnections to excess silicone on the connectors, which prevents a secure fit with the manifolds.
Q2: What medical procedures are most affected by this warning?
The warning primarily affects cardiovascular procedures where contrast dye is injected using NAMIC syringes and procedure kits.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The FDA warned Medline regarding defective NAMIC syringes used in heart procedures, highlighting risks of air embolism and failure to address safety complai...
5 months ago
Explore how patient retention in hospitals relies on clinical trust and longitudinal continuity rather than aggressive commercial conversion. Healthcare leaders highlight evidence-based care, post-discharge adherence, and operational accountability as the true drivers of sustainable patient lifetime value.
Today
A multicentre RCT in China shows that the PAICS AI system significantly boosts sonographer sensitivity in detecting fetal intracranial malformations by 8.7% without compromising specificity, offering promising diagnostic support for prenatal neurosonography.
Today
A recent study highlights the utility of two-dimensional speckle tracking echocardiography in assessing right atrial mechanics in OSAHS. Progressive reductions in reservoir and conduit strain, coupled with elevated contraction strain, signal early right heart remodeling correlated with apnea severity.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Yesterday
The Supreme Court questioned FSSAI's phased warning approach, urging single-phase implementation for foods exceeding limits in any nutrient of concern. Backed by ICMR-NIN recommendations, the proposed red hexagonal warnings target added sugar, salt, and fat to combat India's escalating chronic disease epidemic.
Today
